AstraZeneca Offers $2 Billion for Fusion Pharmaceuticals to Boost Cancer Radiopharma Business

• Fusion Pharmaceuticals received a $2 billion takeover offer from AstraZeneca, sending its stock price surging 97% to record highs.

• The deal highlights growing interest in radiopharmaceuticals - drugs using radioactive isotopes to target cancer cells.

• Fusion's technology gives AstraZeneca a competitive advantage in radiopharmaceutical production.

• The deal offers $2 billion upfront and $3 per share contingent on an FDA review milestone.

• Analysts are bullish on radiopharmaceuticals providing growth opportunities for years to come.